5 completed. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
Follow B Acute Lymphoblastic Leukemia: new trials by email Literature Review of B Acute Lymphoblastic Leukemia trials Research Report on B Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL Blinatumomab - B Acute Lymphoblastic Leukemia | Phase 2 | Completed | Chen Suning | 35 | 2022-09-08 | 2024-09-19 |
| CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) AUTO3 (CD19/22 CAR T cells - B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Autolus Limited | 23 | 2017-06-26 | 2021-02-01 |
| Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia Laboratory Biomarker Analysis, Pharmacological Study, Sapanisertib - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2017-04-06 | 2025-03-03 |
| Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Azacitidine, Biospecimen Collection, Computed Tomography - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2017-04-01 | 2025-02-27 |
| Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease Blinatumomab, TKI - Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 37 | 2015-09-14 | 2026-09-25 |
Burkitt Lymphoma (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia, Biphenotypic, Acute (1) · Neoplasm, Residual (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
DNA Virus Infections (5) · Epstein-Barr Virus Infections (5) · Hemic and Lymphatic Diseases (5) · Herpesviridae Infections (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Infections (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoma, B-Cell (5) · Lymphoma, Non-Hodgkin (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Tumor Virus Infections (5)
blinatumomab (2) · Azacitidine (1) · Calcium Dobesilate (1) · Cyclophosphamide (1) · Cytarabine (1) · Daunorubicin (1) · Dexamethasone (1) · Hydrocortisone (1) · Leucovorin (1) · Magnetic Resonance Spectroscopy (1) · Mercaptopurine (1) · Methotrexate (1) · Methylprednisolone (1) · N,N-dicyclohexyl-isoborneol-10-sulfonamide (1) · Prednisolone (1)
National Cancer Institute (NCI) (2) · Autolus Limited (1) · Chen Suning (1) · M.D. Anderson Cancer Center (1)
United States (3) · Australia (1) · Canada (1) · China (1) · Puerto Rico (1) · United Kingdom (1)
Aref Al-Kali (1) · Elias Jabbour (1) · Rishi S Kotecha (1) · Suning Chen, PHD (1)
PMID 35622074, PMID 35713551, PMID 36821767, PMID 37960985, PMID 38867582, PMID 39218935, PMID 39984805
2016 (1), N01CM00099 (1), U10CA180886 (1), UM1CA186686 (1)